Loading...
XNASARCT
Market cap447mUSD
Dec 24, Last price  
16.53USD
1D
0.12%
1Q
-22.43%
Jan 2017
12.45%
IPO
129.26%
Name

Arcturus Therapeutics Holdings Inc

Chart & Performance

D1W1MN
XNAS:ARCT chart
P/E
—
P/S
2.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.47%
Rev. gr., 5y
58.53%
Revenues
158m
-23.33%
00006,138,00020,382,00012,998,00015,753,00020,789,0009,539,00012,359,000205,755,000157,748,000
Net income
-30m
L
-3,929,000-1,579,000-10,548,000-32,834,000-19,449,000-24,603,000-10,902,000-21,785,000-25,721,000-71,364,000-206,863,0009,349,000-29,725,000
CFO
-18m
L
-2,361,000-1,585,000-7,353,000-28,326,000-18,148,000-19,241,000-460,000-20,760,000-6,445,000-42,861,000-135,043,00031,993,000-18,099,000
Dividend
Jan 04, 20130.0085 USD/sh
Earnings
Mar 05, 2025

Profile

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
URL
https://arcturusrx.com/
IPO date
May 22, 2013
Employees
170
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
157,748
-23.33%
205,755
1,564.82%
12,359
29.56%
Cost of revenue
247,961
336,873
387,071
Unusual Expense (Income)
NOPBT
(90,213)
(131,118)
(374,712)
NOPBT Margin
Operating Taxes
1,835
1,295
3,189
Tax Rate
NOPAT
(92,048)
(132,413)
(377,901)
Net income
(29,725)
-417.95%
9,349
-104.52%
(206,863)
189.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
609
411
515
BB yield
-0.07%
-0.09%
-0.05%
Debt
Debt current
4,309
60,655
22,474
Long-term debt
51,814
60,432
49,637
Deferred revenue
42,496
20,071
19,931
Other long-term liabilities
497
2,804
(40,633)
Net debt
(235,882)
(272,890)
(298,896)
Cash flow
Cash from operating activities
(18,099)
31,993
(135,043)
CAPEX
(2,901)
(7,726)
(3,406)
Cash from investing activities
(2,901)
(7,726)
(3,406)
Cash from financing activities
(24,087)
(2,859)
48,016
FCF
(105,561)
(166,112)
(380,602)
Balance
Cash
292,005
391,883
370,492
Long term investments
2,094
515
Excess cash
284,118
383,689
370,389
Stockholders' equity
(367,839)
(338,114)
(347,464)
Invested Capital
719,561
720,877
622,582
ROIC
ROCE
EV
Common stock shares outstanding
26,628
27,093
26,317
Price
31.53
85.91%
16.96
-54.17%
37.01
-14.68%
Market cap
839,581
82.72%
459,497
-52.82%
973,992
10.58%
EV
603,699
186,607
675,096
EBITDA
(87,256)
(129,591)
(373,519)
EV/EBITDA
Interest
767
420
2,674
Interest/NOPBT